Clinical trials: Resectable Esophageal Cancer
Esophageal Cancer
Neoadjuvant Versus Adjuvant Therapy in Treating Resectable Thoracic Esophageal Cancer
This is a prospective Randomized Phase Ⅱ Trial Comparing Preoperative Chemoradiotherapy (Paclitaxel and carboplatin) Followed by Surgery to Surgery Followed by Postoperative Chemoradiotherapy (Paclitaxel and carboplatin) for…
- Trial name
- NCT01463501
- Testing
- Neoadjuvant chemoradiotherapy, Adjuvant chemoradiotherapy
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Zhejiang Cancer Hospital
Esophageal Cancer
Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)
Disease recurrence and metastasis are common after curative treatment for patients with esophageal cancer. Thus, it is important to identify the risk factors to predict disease recurrence and metastasis.
- Trial name
- ECTOP-2005 (NCT05443841)
- Testing
- pleural lavage
- Where
- 11 sites in China
- Volunteers
- 385 people
- Sponsor
- Fudan University
Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy and tumor types.
- Conditions
- Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Cervical Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
- Trial name
- ELEPHAS-04 (NCT06349642)
- Testing
- Biospecimen Collection, Tissue Collection
- Where
- 3 sites in United States
- Volunteers
- 324 people
- Sponsor
- Mayo Clinic
Adenocarcinoma of Esophagus, Squamous Cell Carcinoma of Esophagus
Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer
The purpose of this study is to find out what effects (good and bad) the combination of three chemotherapy drugs (cetuximab, cisplatin, and irinotecan) have on esophageal cancer when given with radiation therapy.
- Trial name
- NCT00165490
- Testing
- Cetuximab, Cisplatin, Irinotecan
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Dana-Farber Cancer Institute
Esophageal Cancer
Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer
The purpose of this study is to see whether or not the combination of cisplatin, irinotecan and radiation, followed by surgery, followed by oral Sutent, is effective and safe for patients with resectable esophageal cancer.
- Trial name
- NCT00400114
- Testing
- Irinotecan, Cisplatin, Radiation
- Where
- 2 sites in Canada
- Volunteers
- 36 people
- Sponsor
- University Health Network, Toronto
Esophageal Squamous Cell Carcinoma
Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients
An open-label, non-randomized, phase II study to assess the safety and efficacy of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in Borderline Resectable Esophageal Squamous Cell Carcinoma patients
- Trial name
- NCT04548440
- Testing
- Sintilimab, Nab paclitaxel, Cisplatin
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-Sen University Cancer Center
Pancreatic Cancer, Resectable Pancreatic Adenocarcinoma
Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1
Oesogastric and pancreatic adenocarcinomas are poor-prognosis cancers. Incidence of pancreatic cancer drastically increases to such an extent that it will become the second cause of cancer's mortality by 2030.
- Conditions
- Pancreatic Cancer, Resectable Pancreatic Adenocarcinoma, Adenocarcinoma, Resectable Esophageal Cancer
- Trial name
- HEPATOXALI (NCT06649474)
- Testing
- assess the serum HMGB1 concentrations before and after an oxaliplatin-based chemotherapy
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Clermont-Ferrand
Esophageal Cancer
Study of Adebrelimab Combined With Thymalfasin and Chemotherapy for Neoadjuvant Treatment of Esophageal Cancer
This is a prospective, single-arm, multicenter clinical study conducted in China. Patients with pathologically or cytologically confirmed resectable esophageal squamous cell carcinoma will be enrolled to explore the efficacy and…
- Trial name
- NCT07780721
- Testing
- Adebrelimab, Thymalfasin, Chemotherapy
- Where
- China
- Volunteers
- 31 people
- Sponsor
- The Affiliated Hospital of Putian University
Esophageal Cancer, Gastric Cancer
Surgery With or Without Combination Chemotherapy in Treating Patients With Cancer of the Esophagus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not known whether combining chemotherapy with surgery is more effective than surgery alone.
- Trial name
- NCT00002883
- Testing
- cisplatin, fluorouracil, adjuvant therapy
- Where
- France
- Volunteers
- 250 people
- Sponsor
- UNICANCER
Esophageal Squamous Cell Carcinoma by AJCC V8 Stage, Resectable Esophageal Cancer
Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal Cancer
Neoadjuvant chemoradiotherapy (CRT) followed by surgery has become the standard treatment option for locally advanced esophageal cancer (EC).
- Trial name
- NCT04006041
- Testing
- Toripalimab, Paclitaxel/cisplatin, Intensity-modulated radiotherapy
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Jianhua Fu
Esophageal Cancer, Stage II, Esophageal Cancer Stage III
PDL-1 Targeting in Resectable Oesophageal Cancer
Objectives The primary objective of this study is to assess the feasibility of preoperative treatment with atezolizumab combined with preoperative chemoradiation (carboplatin, paclitaxel and radiation) in terms of completion of…
- Trial name
- PERFECT (NCT03087864)
- Testing
- Atezolizumab, Carboplatin, Paclitaxel
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Resectable Esophageal Squamous Cell Carcinoma
Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC
This trial is conducted in patients with resectable locally advanced esophageal squamous cell carcinoma. The investigators plan to enroll 46 patients with resectable locally advanced esophageal cancer in Tianjin cancer hospital.
- Trial name
- NCT07457528
- Testing
- HLX10, Chemotherapy, Nimotuzumab
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Locally Advanced Esophageal Cancer, Gastroesophageal Junction Cancer
Comprehensive Perioperative Program Based on Prehabilitation, Nutritional Intervention and Psychological Support for Patients With Locally Advanced Operable Oesophagogastric Cancer
Perioperative chemotherapy (CHT) or CHT/RT combined with surgery is the standard therapeutic approach for the treatment of locally advanced cancer of the esophagus, gastroesophageal junction (GEJ), and stomach.
- Conditions
- Locally Advanced Esophageal Cancer, Gastroesophageal Junction Cancer, Gastric Cancer
- Trial name
- OESOFIT (NCT07671625)
- Testing
- Cardiorespiratory fitness (FsPS), Exercises you can do on your own at home, Enhanced Recovery After Surgery ERAS
- Where
- Czechia
- Volunteers
- 60 people
- Sponsor
- Masaryk Memorial Cancer Institute